Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Common Equity (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Common Equity for 11 consecutive years, with $671.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 23.0% to $671.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $671.4 million, a 23.0% decrease, with the full-year FY2025 number at $671.4 million, down 23.0% from a year prior.
  • Common Equity was $671.4 million for Q4 2025 at Intellia Therapeutics, down from $748.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.2 billion in Q4 2022 to a low of $494.8 million in Q2 2021.
  • A 5-year average of $911.1 million and a median of $958.2 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 235.87% in 2021, then dropped 26.34% in 2025.
  • Intellia Therapeutics' Common Equity stood at $1.0 billion in 2021, then rose by 18.78% to $1.2 billion in 2022, then fell by 15.01% to $1.1 billion in 2023, then dropped by 16.97% to $872.0 million in 2024, then decreased by 23.0% to $671.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Common Equity are $671.4 million (Q4 2025), $748.4 million (Q3 2025), and $715.3 million (Q2 2025).